Drugs in MeSH Category Antirheumatic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	CYCLOSPORINE	cyclosporine	EMULSION;OPHTHALMIC	209064-001	Jan 21, 2026	AB	RX	No	No
Hikma	CYCLOPHOSPHAMIDE	cyclophosphamide	CAPSULE;ORAL	203856-002	Sep 16, 2013	AB	RX	Yes	Yes
Dr Reddys Labs Sa	CYCLOSPORINE	cyclosporine	SOLUTION;ORAL	065054-001	Dec 18, 2001		DISCN	No	No
Shorla	JYLAMVO	methotrexate	SOLUTION;ORAL	212479-001	Nov 29, 2022		RX	Yes	Yes			Y
Hikma	CYCLOSPORINE	cyclosporine	INJECTABLE;INJECTION	065004-001	Oct 29, 1999	AP	RX	No	No

Antirheumatic Agents Market Analysis and Financial Projection

Last updated: April 24, 2026

Antirheumatic Agents (MeSH): Market Dynamics and Patent Landscape

What does “Antirheumatic Agents” cover in MeSH terms?

NLM MeSH class Antirheumatic Agents is a therapeutic category that includes drugs used to treat rheumatic diseases. In practice, the MeSH grouping overlaps heavily with the major commercial therapeutic clusters in autoimmune rheumatology: conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), targeted synthetic DMARDs (tsDMARDs), and biologic DMARDs (bDMARDs), plus adjunct symptom-control agents.

MeSH placement matters because it determines how claims are mapped in patent datasets and how market trackers bucket filings. For patent analytics, the most actionable view is to treat MeSH as a top-down umbrella and then break out patent activity by mechanism family: TNF inhibitors, IL-6 pathway inhibitors, CTLA4-Ig and CD80/86 axis, IL-17 axis, IL-23/Th17 axis (psoriatic arthritis), JAK inhibitors, PDE4 inhibitor (psoriasis/psoriatic overlap), Syk inhibitors (emerging), and other kinase-directed agents, plus older csDMARDs and combination regimens.

---

How is the Antirheumatic Agents market behaving by mechanism?

1) Market shift: from TNF-dominance to multi-pathway competition

Across immunology-driven rheumatology, sales growth has concentrated in oral small molecules and pathway-diversifying biologics, especially JAK inhibitors and IL-6/IL-17/IL-23 axis programs. TNF inhibitors remain large, but growth increasingly comes from:

• Earlier lines of therapy expansion for targeted small molecules
• Switching behavior (patients move after inadequate response)
• Mechanism switching between biologics and within biologics

2) Competitive dynamics: broad class overlap across indications

“Antirheumatic Agents” includes drugs used across multiple labels that share payer incentives and trial infrastructure:

• Rheumatoid arthritis (RA)
• Psoriatic arthritis (PsA)
• Ankylosing spondylitis (AS) / axial spondyloarthritis
• Juvenile idiopathic arthritis (JIA) and overlapping pediatric indications

This cross-indication structure drives patent filing concentration around:

• Same mechanism, new anatomical site claims (e.g., axial versus peripheral disease)
• New patient subgroups (biomarker-defined)
• New combination claims (with MTX, with biologic class controls, or as monotherapy)

3) Pricing and reimbursement pressures increase “lifecycle patenting”

As biosimilar entry rises for key biologics, brand manufacturers lean harder on:

• Next-generation molecules (same pathway, improved properties)
• Formulation and dosing innovations
• Method-of-use extensions that sustain exclusivity beyond primary compound protection
• Combination and line-of-therapy claims

This is visible in patenting patterns: fewer “first-in-class” breakthroughs and more second-wave IP that targets label expansion and patent term management.

---

What does the patent landscape look like at a practical level?

Patent strategy by molecule class

A. Biologics (bDMARDs) Patent themes cluster around:

• Monoclonal antibody sequences and binding characteristics
• Engineered properties (Fc modifications, reduced immunogenicity, altered binding kinetics)
• Manufacturing/process improvements
• Device- and delivery-related claims
• Method-of-use tied to specific indications and patient populations

B. Small molecules (tsDMARDs) Patent themes cluster around:

• Compound-level claims and tautomeric/solvate variants
• Polymorph/crystal form coverage
• Compositions and dosing regimens
• Combination regimens
• Biomarker stratification and specific clinical endpoints

C. JAK inhibitor ecosystem The JAK family shows repeated patterns of:

• Selectivity-driven second generation (JAK1/TYK2, JAK1/2, etc.)
• Pediatric plans and extension studies
• Long-term safety and effectiveness claims
• Formulation IP for once-daily dosing and specific release profiles

D. Biosimilar pressure Biosimilar entrants trigger counter-IP plays:

• Orange Book and exclusivity mapping
• Patent thickets around “use” and “formulation”
• Litigation focused on claim construction and product equivalence

---

Which patent families dominate antirheumatic IP by therapeutic mechanism?

The “dominant” families depend on sub-indication, but the overall patent gravity typically centers on these mechanism families (these are the primary commercial and litigated classes in antirheumatic therapeutics globally):

Mechanism family (Antirheumatic umbrella)	Typical patent claim focus	Market behavior it ties to
TNF inhibitors	Sequence variants, biosimilar-blocking patents, use/combination	High revenue base, heavy biosimilar pressure
IL-6 pathway (e.g., IL-6, IL-6R)	mAb engineering + method-of-use	Strong RA positioning, expansion to other arthritides
CTLA4-Ig (T-cell costimulation)	Fusion protein design and dosing	Oriented to RA/selected combos
IL-17 axis	mAb sequences/epitopes and patient-response stratification	PsA/AS gravity; mechanism switching
IL-23 axis	mAb class filings for spondyloarthritis/PsA	Post-TNF pathway competition
JAK inhibitors	Compound selectivity, dosing regimens, formulations	Oral convenience + rapid uptake; frequent line expansion
Syk and other kinases (emerging)	Target engagement + small-molecule coverage	Late-stage competitive crowding around novel MOAs
csDMARDs (MTX, etc.)	Process, salt forms, combinations, regimen optimization	Lower new patent frequency; lifecycle claims persist

---

Where do the main patent expirations and exclusivity cliffs concentrate?

The most relevant “cliff” concept for business planning is not a single date but a staggered sequence of primary compound expiration, biologic exclusivity, and method-of-use extension.

In antirheumatics, the cliffs commonly cluster in waves driven by:

• bDMARD primary patent expiration
• Biosimilar launch timing
• Method-of-use exclusivity tied to trial results
• Reformulation and delivery patents

These waves are repeatedly reflected in Orange Book and global regulatory exclusivity structures, with frequent post-expiration competitiveness within 12 to 36 months.

---

How do major regulatory frameworks shape antirheumatic patent strategies?

U.S. Orange Book and exclusivity management

For branded drugs, the U.S. Orange Book listing and associated exclusivity mechanisms influence how biosimilar and generic applicants can challenge or enter.

Key references:

• FDA Orange Book for approved drug products and exclusivity-related listings. ([1])

Hatch-Waxman and biologics pathways (U.S.)

Patent listing and litigation timing determine entry windows, especially for small molecules.

• FDA overview of drug approval pathways including patent-related listing context. ([2])

MeSH mapping and evidence linkage

MeSH classification affects downstream analytics and evidence retrieval. The MeSH hierarchy for therapeutic categories is maintained by NLM, and it is used for indexing and structured searching.

• NLM MeSH Browser entry for Antirheumatic Agents. ([3])

---

What does the patent landscape imply for R&D prioritization?

1) IP leverage comes from combinations, patient selection, and delivery

Given class-level competition and biosimilar pressure, the highest-probability patent value typically arises from:

• Method-of-use claims tied to specific lines of therapy
• Combination regimens (drug A with csDMARD, or drug A with another targeted agent as supported by trial designs)
• Patient subgroups (biomarkers, prior treatment failures, disease severity categories)

2) Second-generation chemistry and next-step MOAs matter

When the first-in-class compound approaches expiry, developers protect the portfolio by:

• Selectivity-improved variants
• New target engagement strategies
• Better dosing and safety profiles that justify label expansions

3) Litigation readiness is part of portfolio design

In antirheumatics, litigation risk is structurally higher because:

• High market size creates economic incentive
• Multiple entrants focus on switching and line-of-therapy indications
• Biosimilar adoption changes the payoff matrix quickly

This affects patent drafting: claim breadth, fallback positioning, and careful alignment between clinical endpoints and method-of-use claims.

---

What is the investment-relevant view: where value sits next?

Likely value pockets

Across antirheumatics, the next value tends to sit in:

• Mechanism expansion from current anchors into adjacent phenotypes (RA to axial, PsA to axial overlap)
• Oral and convenience-driven regimens (adherence and payer preference)
• Safety and tolerability differentiated claims that support continued switching

Risk pockets

• Patent thicket overreach (claims that cannot be sustained)
• Biosimilar timing that compresses revenue before method-of-use value materializes
• Regulatory label overlap that reduces incremental differentiation

---

Key takeaways

• MeSH “Antirheumatic Agents” is a high-overlap umbrella across RA, PsA, AS/axSpA, and JIA, so patent activity clusters by mechanism family more than by MeSH itself.
• Competition is shifting from single-pathway dominance to multi-mechanism ecosystems, driven by JAK inhibitors and IL-6/IL-17/IL-23 pathway diversification.
• Patent value increasingly comes from lifecycle IP: method-of-use, combination regimens, dosing and formulation, and patient-selection claims aligned to registrational trial endpoints.
• Exclusivity cliffs are staggered and mechanism-specific, with biosimilar entry risk shaping R&D and portfolio strategy.
• Regulatory listing frameworks (Orange Book and related FDA pathways) strongly influence how portfolios defend revenue windows.

---

FAQs

1. How should an investor map MeSH “Antirheumatic Agents” to patent analytics?
   Use MeSH as the index layer, then partition by mechanism family (TNF, IL-6, IL-17, IL-23, CTLA4-Ig, JAK, kinase-directed) to align patent families with clinical differentiation.

2. What patent claim types most often carry commercial value in antirheumatics?
   Compound/formulation coverage plus method-of-use and combination regimens tied to specific patient populations and lines of therapy.

3. Do biosimilar dynamics change patent strategy in this therapeutic area?
   Yes. They increase the emphasis on lifecycle IP, enforceability planning, and tight alignment between trial outcomes and claim language.

4. Where do exclusivity and entry timelines typically concentrate?
   In waves driven by primary patent expiry for key biologics and the associated timing of biosimilar launches and method-of-use extensions.

5. What is the highest-signal lens for near-term value creation?
   Next-generation differentiation within existing mechanisms plus oral convenience strategies, paired with label expansion work that produces defensible method-of-use claims.

---

References

[1] FDA. (n.d.). Drugs@FDA: Orange Book. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
[2] FDA. (n.d.). Drug Development and Approval Process. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs
[3] National Library of Medicine. (n.d.). MeSH Browser: Antirheumatic Agents. https://meshb.nlm.nih.gov/